GLG News by Psychiatrists who Treat Mood Disorders (US)

This article tells you only that the drugs are equally effective, but not what that really means in real life.

Astra Zeneca is pursuing important medical and, of course, commercial goals by seeking the expanded clinical indications of major depression and generalized anxiety disorder for Seroquel XR, heir to blockbuster Seroquel (quetiapine).  This latest EU submission culminates regulatory submissions...

This "report" tells you nothing that you need to know in order to assess the validity of these studies.  We have always known that St. John's Wort has some effectiveness---but it certainly does not come without side-effects.  Where is the information about the length of the studies, the relative...

Gamma secretase inhibitors are one of several kinds of drugs being studied for the prevention/amelioration of Alzheimer's.  In concept they make sense.

All is not as it seems when reported in the press, especially the non-scientific press.

-Pharmacogenetic tests have not made it into the treatment or assessment process for most physicians. -Until the cost for these tests become negligible -- or, included in the cost of a particular antidepressant -- psychopharmacogenetic testing will not make it into the mainstream. 

“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development.  Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...

‘One drug, many uses’ can make lots of sense clinically and commercially.   Seeking additional FDA indications for a specific drug has obvious business benefits:  greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...

Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report.   Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...

We need to look to the cause of why we prescribe antipsychotics to patients with dementia.  We have very few tools to use and sometimes these drugs are a necessity.